<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="219">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01240005</url>
  </required_header>
  <id_info>
    <org_study_id>DCCIK002</org_study_id>
    <nct_id>NCT01240005</nct_id>
  </id_info>
  <brief_title>Cytokine Induced Killer Cells Stimulated by DC Immunotherapy for Renal Cell Carcinoma</brief_title>
  <official_title>A Phase I/II Evaluation of Cytokine Induced Killer Cells Stimulated by DC(DCIK) Immunotherapy in Patients With Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qingdao University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qingdao University</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      30% of renal cell carcinoma patients have metastases, mostly in lung, liver and bones at the
      time of diagnosis. Because of poor response to radiation therapy or chemotherapy, several
      studies have been initiated to find alternative therapeutic options.

      Cytokine induced killer cells(CIK) are an unique population of cytotoxic T lymphocytes with
      a characteristic CD3+ CD56+ phenotype; they can be generated from cytokine cocktail-induced
      peripheral blood mononuclear cells (PBMC). CIK cells represent strong anti-tumor
      cytotoxicity in vitro and in vivo. Interestingly,the anti-tumor activity of CIK cells can be
      enhanced by incubation with dendritic cells (DC), which are the most potent antigen
      (Ag)-presenting cells.

      The purpose of this study was to evaluate the clinical efficacy of DC-activated CIK cell
      treatment following regular therapy and the effects of this therapy on immune responses in
      patients with renal cell carcinoma after surgery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification:  Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response, Time to recurrence, Progression-free, Cellular immunity.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>DCIK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DCIK</intervention_name>
    <description>Renal cell carcinoma patients were treated with three intravenous infusions of DC activated CIK cells at 1-day intervals. Clinical examinations of these patients were performed.</description>
    <arm_group_label>DCIK</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female or male, adult patients of 18 to 75 years of age at time of diagnosis that
             qualify for standard treatment including surgery.

          2. Histologically confirmed diagnosis of renal cell carcinoma.

          3. Newly diagnosed or recurrent disease.

          4. Karnofsky performance status 60-100.

          5. Life expectancy â‰¥ 12 weeks.

          6. Written informed consent of patient and/or legal guardian.

          7. Must be off steroid at least two weeks prior to vaccination.

          8. Hematologic and metabolic panel results will be within the parameters of the
             protocol.

          9. Normal renal function in the kidney.

         10. Adequate function of liver,lung and heart.

         11. Negative pregnancy test

         12. Fertile patients must use effective contraception

         13. Serologically negative for HIV,HBV,HCV.

         14. Syphilis serology negative

         15. Patient must have no prior sensitivity to the components of the dendritic cell
             vaccine.

        Exclusion Criteria:

          1. Anti-neoplastic chemotherapy or radiotherapy during 4 weeks before entering the
             study.

          2. Presence of acute infection.

          3. Inability to obtain informed consent because of psychiatric or complicating medical
             problems.

          4. Patients with other significant illness including severe allergy, asthma, angina
             pectoris or congestive heart failure.

          5. Subjects with organ allografts.

          6. Known history of autoimmune disorder.

          7. Pregnancy or breast-feeding.

          8. Positive for hepatitis B, C, HIV, syphilis.

          9. Patients unwilling to perform a save method of birth control.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongheng An</last_name>
    <role>Study Chair</role>
    <affiliation>The affilited hospital of medical college,Qingdao university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yongheng An</last_name>
    <phone>+86-532-82911676</phone>
    <email>anyongheng@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xuefeng Zhang</last_name>
    <phone>+86-13789861225</phone>
    <email>xuefengzhang15@126.com,qdstemcell@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stem cell cencter of the affiliated hospital of medical colledge,qingdao university</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <lastchanged_date>November 12, 2010</lastchanged_date>
  <firstreceived_date>November 12, 2010</firstreceived_date>
  <responsible_party>
    <name_title>An Yongheng,Li Yanjiang,Gao Hong,Zhang Xuefeng</name_title>
    <organization>The Affilited Hospital of Medical College,Qingdao University</organization>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
</clinical_study>
